How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "8581"
  ["article_id"]=>
  string(4) "8581"
  [1]=>
  string(41) "J&J Identifies COVID-19 Vaccine Candidate"
  ["article_title"]=>
  string(41) "J&J Identifies COVID-19 Vaccine Candidate"
  [2]=>
  string(147) "&#nl        Johnson and Johnson said it has a potential COVID-19 vaccine and plans to begin phase 1 human trials no later than September.&#nl      "
  ["short_description"]=>
  string(147) "&#nl        Johnson and Johnson said it has a potential COVID-19 vaccine and plans to begin phase 1 human trials no later than September.&#nl      "
  [3]=>
  string(147) "&#nl        Johnson and Johnson said it has a potential COVID-19 vaccine and plans to begin phase 1 human trials no later than September.&#nl      "
  ["description"]=>
  string(147) "&#nl        Johnson and Johnson said it has a potential COVID-19 vaccine and plans to begin phase 1 human trials no later than September.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(80) "https://www.fdanews.com/articles/196447-jj-identifies-covid-19-vaccine-candidate"
  ["blog_url"]=>
  string(80) "https://www.fdanews.com/articles/196447-jj-identifies-covid-19-vaccine-candidate"
  [15]=>
  string(19) "2020-03-31 07:09:57"
  ["add_date"]=>
  string(19) "2020-03-31 07:09:57"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:06"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

J&J Identifies COVID-19 Vaccine Candidate

&#nl Johnson and Johnson said it has a potential COVID-19 vaccine and plans to begin phase 1 human trials no late

array(40) {
  [0]=>
  string(4) "8528"
  ["article_id"]=>
  string(4) "8528"
  [1]=>
  string(82) "Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer"
  ["article_title"]=>
  string(82) "Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer"
  [2]=>
  string(150) "30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extens"
  ["short_description"]=>
  string(150) "30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extens"
  [3]=>
  string(238) "30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)..."
  ["description"]=>
  string(238) "30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(240) "https://www.drugs.com/newdrugs/imfinzi-durvalumab-approved-us-extensive-stage-small-cell-lung-cancer-5193.html?utm_source=ddc&utm_medium=rss&utm_campaign=Imfinzi+%28durvalumab%29+Approved+in+the+US+for+Extensive-Stage+Small+Cell+Lung+Cancer"
  ["blog_url"]=>
  string(240) "https://www.drugs.com/newdrugs/imfinzi-durvalumab-approved-us-extensive-stage-small-cell-lung-cancer-5193.html?utm_source=ddc&utm_medium=rss&utm_campaign=Imfinzi+%28durvalumab%29+Approved+in+the+US+for+Extensive-Stage+Small+Cell+Lung+Cancer"
  [15]=>
  string(19) "2020-03-31 06:03:10"
  ["add_date"]=>
  string(19) "2020-03-31 06:03:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:18:00"
  ["create_at"]=>
  string(19) "2020-03-31 11:18:00"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment 

array(40) {
  [0]=>
  string(4) "8659"
  ["article_id"]=>
  string(4) "8659"
  [1]=>
  string(64) "Bioventus CEO Tony Bihl to Retire, Ken Reali Appointed Successor"
  ["article_title"]=>
  string(64) "Bioventus CEO Tony Bihl to Retire, Ken Reali Appointed Successor"
  [2]=>
  string(150) "Bioventus has announced that CEO Tony Bihl will retire on April 30. The Durham, NC-based company has appointed Ken Reali as his successor. He will als"
  ["short_description"]=>
  string(150) "Bioventus has announced that CEO Tony Bihl will retire on April 30. The Durham, NC-based company has appointed Ken Reali as his successor. He will als"
  [3]=>
  string(352) "Bioventus has announced that CEO Tony Bihl will retire on April 30. The Durham, NC-based company has appointed Ken Reali as his successor. He will also join the privately held firm’s board of managers starting on April 20. Reali is coming to Bioventus from Utah-based Clinical Innovations, where he is president and CEO. His experience […]"
  ["description"]=>
  string(352) "Bioventus has announced that CEO Tony Bihl will retire on April 30. The Durham, NC-based company has appointed Ken Reali as his successor. He will also join the privately held firm’s board of managers starting on April 20. Reali is coming to Bioventus from Utah-based Clinical Innovations, where he is president and CEO. His experience […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(110) "https://xconomy.com/raleigh-durham/2020/03/30/bioventus-ceo-tony-bihl-to-retire-ken-reali-appointed-successor/"
  ["blog_url"]=>
  string(110) "https://xconomy.com/raleigh-durham/2020/03/30/bioventus-ceo-tony-bihl-to-retire-ken-reali-appointed-successor/"
  [15]=>
  string(19) "2020-03-31 05:49:31"
  ["add_date"]=>
  string(19) "2020-03-31 05:49:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:33"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Bioventus CEO Tony Bihl to Retire, Ken Reali Appointed Successor

Bioventus has announced that CEO Tony Bihl will retire on April 30. The Durham, NC-based company has appointed Ken Reali

array(40) {
  [0]=>
  string(4) "8588"
  ["article_id"]=>
  string(4) "8588"
  [1]=>
  string(90) "Axiom Real-Time Metrics Mobilizes to Respond to Vital Clinical Trial Needs During COVID-19"
  ["article_title"]=>
  string(90) "Axiom Real-Time Metrics Mobilizes to Respond to Vital Clinical Trial Needs During COVID-19"
  [2]=>
  string(158) "TORONTO, March  30, 2020  (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is r"
  ["short_description"]=>
  string(158) "TORONTO, March  30, 2020  (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is r"
  [3]=>
  string(275) "
TORONTO, March  30, 2020  (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is responding to the unique and unprecedented circumstances the COVID-19 global pandemic.
"
  ["description"]=>
  string(275) "
TORONTO, March  30, 2020  (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is responding to the unique and unprecedented circumstances the COVID-19 global pandemic.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(161) "http://www.globenewswire.com/news-release/2020/03/30/2008745/0/en/Axiom-Real-Time-Metrics-Mobilizes-to-Respond-to-Vital-Clinical-Trial-Needs-During-COVID-19.html"
  ["blog_url"]=>
  string(161) "http://www.globenewswire.com/news-release/2020/03/30/2008745/0/en/Axiom-Real-Time-Metrics-Mobilizes-to-Respond-to-Vital-Clinical-Trial-Needs-During-COVID-19.html"
  [15]=>
  string(19) "2020-03-31 05:32:00"
  ["add_date"]=>
  string(19) "2020-03-31 05:32:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Axiom Real-Time Metrics Mobilizes to Respond to Vital Clinical Trial Needs During COVID-19

TORONTO, March 30, 2020 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), pre

array(40) {
  [0]=>
  string(4) "8589"
  ["article_id"]=>
  string(4) "8589"
  [1]=>
  string(33) "Supernus Provides Business Update"
  ["article_title"]=>
  string(33) "Supernus Provides Business Update"
  [2]=>
  string(150) "ROCKVILLE, Md., March  30, 2020  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and"
  ["short_description"]=>
  string(150) "ROCKVILLE, Md., March  30, 2020  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and"
  [3]=>
  string(314) "
ROCKVILLE, Md., March  30, 2020  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provides a business update related to the COVID-19 situation.
"
  ["description"]=>
  string(314) "
ROCKVILLE, Md., March  30, 2020  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provides a business update related to the COVID-19 situation.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(104) "http://www.globenewswire.com/news-release/2020/03/30/2008735/0/en/Supernus-Provides-Business-Update.html"
  ["blog_url"]=>
  string(104) "http://www.globenewswire.com/news-release/2020/03/30/2008735/0/en/Supernus-Provides-Business-Update.html"
  [15]=>
  string(19) "2020-03-31 05:20:00"
  ["add_date"]=>
  string(19) "2020-03-31 05:20:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Supernus Provides Business Update

ROCKVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical 

array(40) {
  [0]=>
  string(4) "8590"
  ["article_id"]=>
  string(4) "8590"
  [1]=>
  string(119) "AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE"
  ["article_title"]=>
  string(119) "AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE"
  [2]=>
  string(155) "– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ –"
  ["short_description"]=>
  string(155) "– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ –"
  [3]=>
  string(207) "
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ –
"
  ["description"]=>
  string(207) "
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ –
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(190) "http://www.globenewswire.com/news-release/2020/03/30/2008724/0/en/AETERNA-ZENTARIS-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2019-FINANCIAL-AND-OPERATING-RESULTS-AND-PROVIDES-BUSINESS-UPDATE.html"
  ["blog_url"]=>
  string(190) "http://www.globenewswire.com/news-release/2020/03/30/2008724/0/en/AETERNA-ZENTARIS-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2019-FINANCIAL-AND-OPERATING-RESULTS-AND-PROVIDES-BUSINESS-UPDATE.html"
  [15]=>
  string(19) "2020-03-31 05:00:00"
  ["add_date"]=>
  string(19) "2020-03-31 05:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS

– Strengthened cash position with recently closed financing as well as roy

array(40) {
  [0]=>
  string(4) "8591"
  ["article_id"]=>
  string(4) "8591"
  [1]=>
  string(75) "Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update"
  ["article_title"]=>
  string(75) "Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update"
  [2]=>
  string(150) "SAN DIEGO, March  30, 2020  (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended"
  ["short_description"]=>
  string(150) "SAN DIEGO, March  30, 2020  (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended"
  [3]=>
  string(497) "
SAN DIEGO, March  30, 2020  (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2019 and provided a business update.
"
  ["description"]=>
  string(497) "
SAN DIEGO, March  30, 2020  (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2019 and provided a business update.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(146) "http://www.globenewswire.com/news-release/2020/03/30/2008711/0/en/Adamis-Pharmaceuticals-Announces-2019-Financial-Results-and-Business-Update.html"
  ["blog_url"]=>
  string(146) "http://www.globenewswire.com/news-release/2020/03/30/2008711/0/en/Adamis-Pharmaceuticals-Announces-2019-Financial-Results-and-Business-Update.html"
  [15]=>
  string(19) "2020-03-31 04:40:00"
  ["add_date"]=>
  string(19) "2020-03-31 04:40:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update

SAN DIEGO, March 30, 2020 (GLOBE NEWSWIRE) -- 

array(40) {
  [0]=>
  string(4) "8592"
  ["article_id"]=>
  string(4) "8592"
  [1]=>
  string(150) "CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline"
  ["article_title"]=>
  string(150) "CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline"
  [2]=>
  string(152) "Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payme"
  ["short_description"]=>
  string(152) "Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payme"
  [3]=>
  string(203) "
Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payment to CytomX
"
  ["description"]=>
  string(203) "
Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payment to CytomX
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(218) "http://www.globenewswire.com/news-release/2020/03/30/2008690/0/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-AbbVie-CD71-Partnership-and-Provides-Update-on-Impact-of-COVID-19-on-Clinical-Stage-Pipeline.html"
  ["blog_url"]=>
  string(218) "http://www.globenewswire.com/news-release/2020/03/30/2008690/0/en/CytomX-Therapeutics-Announces-Milestone-Achievement-in-AbbVie-CD71-Partnership-and-Provides-Update-on-Impact-of-COVID-19-on-Clinical-Stage-Pipeline.html"
  [15]=>
  string(19) "2020-03-31 04:15:00"
  ["add_date"]=>
  string(19) "2020-03-31 04:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Prov

Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-D

array(40) {
  [0]=>
  string(4) "8593"
  ["article_id"]=>
  string(4) "8593"
  [1]=>
  string(83) "Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results"
  ["article_title"]=>
  string(83) "Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results"
  [2]=>
  string(150) "PALATINE, Ill., March  30, 2020  (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, developm"
  ["short_description"]=>
  string(150) "PALATINE, Ill., March  30, 2020  (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, developm"
  [3]=>
  string(414) "
PALATINE, Ill., March  30, 2020  (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and twelve months ended December 31, 2019.
"
  ["description"]=>
  string(414) "
PALATINE, Ill., March  30, 2020  (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and twelve months ended December 31, 2019.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(154) "http://www.globenewswire.com/news-release/2020/03/30/2008694/0/en/Acura-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html"
  ["blog_url"]=>
  string(154) "http://www.globenewswire.com/news-release/2020/03/30/2008694/0/en/Acura-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html"
  [15]=>
  string(19) "2020-03-31 04:15:00"
  ["add_date"]=>
  string(19) "2020-03-31 04:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results

PALATINE, Ill., March 30, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty

array(40) {
  [0]=>
  string(4) "8594"
  ["article_id"]=>
  string(4) "8594"
  [1]=>
  string(102) "Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital"
  ["article_title"]=>
  string(102) "Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital"
  [2]=>
  string(150) "LA JOLLA, Calif., March  30, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understand"
  ["short_description"]=>
  string(150) "LA JOLLA, Calif., March  30, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understand"
  [3]=>
  string(476) "
LA JOLLA, Calif., March  30, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. 
"
  ["description"]=>
  string(476) "
LA JOLLA, Calif., March  30, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(169) "http://www.globenewswire.com/news-release/2020/03/30/2008683/0/en/Equillium-Announces-Common-Stock-Purchase-Agreement-for-up-to-15-Million-with-Lincoln-Park-Capital.html"
  ["blog_url"]=>
  string(169) "http://www.globenewswire.com/news-release/2020/03/30/2008683/0/en/Equillium-Announces-Common-Stock-Purchase-Agreement-for-up-to-15-Million-with-Lincoln-Park-Capital.html"
  [15]=>
  string(19) "2020-03-31 04:07:00"
  ["add_date"]=>
  string(19) "2020-03-31 04:07:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln

LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-

array(40) {
  [0]=>
  string(4) "8595"
  ["article_id"]=>
  string(4) "8595"
  [1]=>
  string(97) "Motus GI Reports Fourth Quarter and Year End 2019 Financial Results and Provides Corporate Update"
  ["article_title"]=>
  string(97) "Motus GI Reports Fourth Quarter and Year End 2019 Financial Results and Provides Corporate Update"
  [2]=>
  string(166) "FORT LAUDERDALE, Fla., March  30, 2020  (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technolog"
  ["short_description"]=>
  string(166) "FORT LAUDERDALE, Fla., March  30, 2020  (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technolog"
  [3]=>
  string(748) "
FORT LAUDERDALE, Fla., March  30, 2020  (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the fourth quarter and year ended December 31, 2019, and provided a corporate update.
"
  ["description"]=>
  string(748) "
FORT LAUDERDALE, Fla., March  30, 2020  (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the fourth quarter and year ended December 31, 2019, and provided a corporate update.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(168) "http://www.globenewswire.com/news-release/2020/03/30/2008672/0/en/Motus-GI-Reports-Fourth-Quarter-and-Year-End-2019-Financial-Results-and-Provides-Corporate-Update.html"
  ["blog_url"]=>
  string(168) "http://www.globenewswire.com/news-release/2020/03/30/2008672/0/en/Motus-GI-Reports-Fourth-Quarter-and-Year-End-2019-Financial-Results-and-Provides-Corporate-Update.html"
  [15]=>
  string(19) "2020-03-31 04:05:00"
  ["add_date"]=>
  string(19) "2020-03-31 04:05:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Motus GI Reports Fourth Quarter and Year End 2019 Financial Results and Provides Corporate

FORT LAUDERDALE, Fla., March 30, 2020 (GLOBE NEWSWIRE) -- 

array(40) {
  [0]=>
  string(4) "8596"
  ["article_id"]=>
  string(4) "8596"
  [1]=>
  string(124) "Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations"
  ["article_title"]=>
  string(124) "Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations"
  [2]=>
  string(118) "ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS"
  ["short_description"]=>
  string(118) "ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS"
  [3]=>
  string(176) "
ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS
"
  ["description"]=>
  string(176) "
ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(195) "http://www.globenewswire.com/news-release/2020/03/30/2008677/0/en/Reata-Pharmaceuticals-Provides-Update-on-the-Impact-of-the-COVID-19-Pandemic-on-Its-Clinical-Studies-and-Business-Operations.html"
  ["blog_url"]=>
  string(195) "http://www.globenewswire.com/news-release/2020/03/30/2008677/0/en/Reata-Pharmaceuticals-Provides-Update-on-the-Impact-of-the-COVID-19-Pandemic-on-Its-Clinical-Studies-and-Business-Operations.html"
  [15]=>
  string(19) "2020-03-31 04:05:00"
  ["add_date"]=>
  string(19) "2020-03-31 04:05:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-31 11:23:14"
  ["create_at"]=>
  string(19) "2020-03-31 11:23:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinic

ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH